Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares ...

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 5.91% on an annualized basis producing an average annual return of 18.0%. Currently, Vertex Pharmaceuticals ...

Industry expert Ralf Gärtner joins as SVP and Regional Manager to spearhead Vertex’s global operationsLONDON, Oct. 30, 2025 ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

A former executive at Microsoft, McAfee and Cisco becomes the fourth CEO in Vertex's 47-year history.

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...